Serum adiponectin as a biomarker for chronic obstructive pulmonary disease and lung cancer and its relation to severity

Abstract

Introduction‘Chronic obstructive pulmonary disease’ (COPD) is an inflammatory disorder associated with airway narrowing and airflow limitation in response to air pollution, gases, and smoking and is associated with morbidity and mortality. Cancer is also considered as a systemic inflammatory disorder where pro-inflammatory cytokines and mediators are released.AimTo evaluate serum adiponectin level in COPD and lung cancer and its importance in detecting and predicting severity.Patients and methodsA total of 40 patients were recruited in the study: 20 had stable COPD and 20 had lung cancer. Moreover, another 10 age-matched and sex-matched individuals were included as a control group. All were subjected to routine laboratory chest radiography, spirometry, and serum adiponectin level measurement.ResultsThe results showed an increase of adiponectin level in both patients with COPD and those with lung cancer, and significant correlation was found between adiponectin level and forced expiratory volume in 1 s and performance status.ConclusionAdiponectin serum level is elevated in both COPD and lung cancer and significantly elevated in severe cases.